Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.37 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.36 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23631136 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL19521448 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL21067800 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL4322755 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL30694316 | 1.00 | MAPK1 (0.52) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL30089312 | 0.91 | LGALS3 (0.54) | MAPK1LGALS3ALDH1A1THRBLGALS8 | |
| SCHEMBL29535303 | 0.90 | MAPK1 (0.53) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL29535351 | 0.90 | MAPK1 (0.53) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL30694301 | 0.89 | MAPK1 (0.62) | MAPK1LGALS3ALDH1A1THRBKDM4E | |
| SCHEMBL29535436 | 0.89 | MAPK1 (0.62) | MAPK1LGALS3ALDH1A1THRBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| CN-119375384-A | Method for in-vitro detection of mucopolysaccharide and pompe disease related biomarker | 浙江博圣生物技术股份有限公司 | 2025-01-28 | — | — | CN | claimed |
| EP-2137204-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | Amicus Therapeutics, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008128089-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | AMICUS THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TEGA THERAPEUTICS, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250273287-A1 | GLYCOSYLATION ENGINEERING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-08-28 | — | — | US | disclosed |
| EP-4602369-A1 | ASSAYS FOR LYSOSOMAL STORAGE DISEASES | Sangamo Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4578462-A2 | DERMAL FILLER COMPOSITIONS | ALLERGAN Industrie, SAS (FR) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179211-A1 | Antibodies and antibody fragments and analogues specific for chondroitin sulfate | VAR2 PHARMACEUTICALS APS (DK) | 2025-06-05 | — | — | US | disclosed |
| US-20250154476-A1 | IMPROVED HEPARAN SULFATE AND METHODS OF MAKING THE SAME | UNIVERSITY OF COPENHAGEN (DK) | 2025-05-15 | — | — | US | disclosed |
| US-12280072-B2 | Oligosaccharide compound for inhibiting intrinsic coagulation factor X-enzyme complex, and preparation method therefor and uses thereof | JIUZHITANG CO., LTD. (CN) | 2025-04-22 | — | — | US | disclosed |
| CN-116120483-B | Chondroitin sulfate C from fish bones, preparation method and application thereof | 中国海洋大学 | 2025-04-15 | — | — | CN | disclosed |
| EP-3969014-A1 | METHOD FOR MODULATING ENDOTHELIAL GLYCOCALYX STRUCTURE | ExThera Medical Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220023186-A1 | DERMAL FILLER COMPOSITIONS | ALLERGAN INDUSTRIE, SAS (FR) | 2022-01-27 | — | — | US | disclosed |
| EP-3842800-A1 | ANALYTICAL METHOD FOR CHONDROITIN SULFATE | JCR Pharmaceuticals Co., Ltd. (JP) | 2021-06-30 | — | — | EP | disclosed |
| US-20210171561-A1 | METHOD FOR ANALYSIS OF CHONDROITIN SULFATE | JCR PHARMACEUTICALS CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| CN-110035766-A | For inhibiting scytitis and determining the method and composition of cancer susceptibility | 新加坡科技研究局 | 2019-07-19 | — | — | CN | disclosed |
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-103492389-A | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors | ORIGENIS GMBH | 2014-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023186-A1 | DERMAL FILLER COMPOSITIONS | CD44, HACD3, CUTA | MAPK1 4233/4885LGALS3 2149/4885ALDH1A1 822/4885 |
| US-12280072-B2 | Oligosaccharide compound for inhibiting intrinsic coagulation factor X-enzyme complex, and preparation method therefor and uses thereof | F11, F8, HABP2 | MAPK1 1480/4885LGALS3 1757/4885ALDH1A1 3775/4885 |
| US-12636307-B2 | In vitro heparin and heparan sulfate compositions and methods of making and using | TPST2, CSGALNACT1, B4GALT1 | MAPK1 2095/4885LGALS3 792/4885ALDH1A1 2044/4885 |
| US-20210171561-A1 | METHOD FOR ANALYSIS OF CHONDROITIN SULFATE | NEFM, SI, MMP13 | MAPK1 1391/4885LGALS3 1412/4885ALDH1A1 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.